Delivering Spatial Biology
to the Clinic
Spatial biology is revolutionizing the discipline of pathology and the practice of medicine. Castle Biosciences is a pioneer in this field, using our spatial analytics platform for biologically aware AI to provide solutions across the precision medicine value chain from drug discovery to clinical diagnostics.
Our biologically aware AI platform delivered to the clinic the world’s first precision medicine test to predict the risk of developing esophageal cancer – one of the world’s most deadly cancers.
Delivering clinically actionable information from tissue biopsies
- are highly complex
- are composed of many cell types and tissue structures
- can have 1000x of active genes, transcripts and expressed proteins
Clinicians need new ways to analyze, interpret and report data.
Only this revolution can change clinical practice.
Our TissueCypher® platform brings together key components of biologically aware AI.
Multiplex assay development
Library of fluorescent immunolabeling assays with robust SOPs for clinical use
Automatic extraction of cellular and molecular information while allowing user-directed generation of biologically relevant features
Model building & validation
Reduction of complexity, classifier development & validation through access to scarce tissue sources and clinical outcomes
>30 issued patents covering spatially resolved analytical methods and first clinical assay
We are applying our biologically aware AI platform across multiple therapeutic areas to deploy our precision medicine assay in the following areas:
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Inflammatory Bowel Disease (Crohn’s and Ulcerative Colitis)
- Pancreatic Cyst Evaluation & Pancreatic Cancer
- NAFLD, NASH and Liver Cancer